Carbonic Anhydrase Modulation Therapy for Neurodegeneration
📖 Wiki Page
idea1141 wordssynced 2026-04-02
Overview
This therapeutic concept targets carbonic anhydrases (CAs) — zinc-metalloenzymes that catalyze the reversible hydration of CO₂ to bicarbonate (CO₂ + H₂O ⇌ H⁺ + HCO₃⁻) — to restore brain pH homeostasis impaired in Alzheimer's disease, Parkinson's disease, and ALS. Carbonic anhydrases play critical roles in maintaining neuronal pH, cerebrospinal fluid production, ion transport, and metabolic regulation.
Rationale
pH dysregulation as common denominator: AD, PD, and ALS brains show 0.1-0.3 pH unit decrease compared to age-matched controls, reflecting neuronal acidification from glycolytic shift and mitochondrial dysfunction[@sun2019; @altamura2024]
CAII downregulation: Postmortem AD brain tissue shows 40-60% reduction in CAII expression — the most abundant brain carbonic anhydrase[@margheri2019]
Cross-disease applicability: pH-dependent mechanisms include amyloid aggregation (enhanced by low pH), alpha-synuclein aggregation, excitotoxicity, and microglial activation — all unified by CA dysregulation[@gonzalez2020; @priem2020]
Repurposing opportunity: FDA-approved CA inhibitors (acetazolamide, dorzolamide, topiramate) have established safety profiles and can be rapidly translated to neurodegeneration trials[@delle2023; @supuran2022]
Disease Coverage
...
Overview
This therapeutic concept targets carbonic anhydrases (CAs) — zinc-metalloenzymes that catalyze the reversible hydration of CO₂ to bicarbonate (CO₂ + H₂O ⇌ H⁺ + HCO₃⁻) — to restore brain pH homeostasis impaired in Alzheimer's disease, Parkinson's disease, and ALS. Carbonic anhydrases play critical roles in maintaining neuronal pH, cerebrospinal fluid production, ion transport, and metabolic regulation.
Rationale
pH dysregulation as common denominator: AD, PD, and ALS brains show 0.1-0.3 pH unit decrease compared to age-matched controls, reflecting neuronal acidification from glycolytic shift and mitochondrial dysfunction[@sun2019; @altamura2024]
CAII downregulation: Postmortem AD brain tissue shows 40-60% reduction in CAII expression — the most abundant brain carbonic anhydrase[@margheri2019]
Cross-disease applicability: pH-dependent mechanisms include amyloid aggregation (enhanced by low pH), alpha-synuclein aggregation, excitotoxicity, and microglial activation — all unified by CA dysregulation[@gonzalez2020; @priem2020]
Repurposing opportunity: FDA-approved CA inhibitors (acetazolamide, dorzolamide, topiramate) have established safety profiles and can be rapidly translated to neurodegeneration trials[@delle2023; @supuran2022]
Disease Coverage
Alzheimer's Disease (AD)
Neuronal acidification: AD brains show decreased brain pH with CAII downregulation in hippocampus and cortex[@altamura2024]
Amyloid intersection: Aβ peptides directly impair CA activity, creating a vicious cycle of acidification and aggregation
Therapeutic approach: CA inhibitors (acetazolamide) may restore pH and reduce amyloid aggregation propensity
pH decline: Normal aging associated with gradual decrease in brain pH and CA activity
Prevention potential: CA modulation may slow age-related pH decline and preserve neuronal function
Evidence Base
Preclinical Evidence
| Evidence Type | Source | Key Finding | Relevance | |---------------|--------|-------------|-----------| | CA/AD pH | [Cell Calcium 2019, Sun et al.](https://doi.org/10.1016/j.ceca.2019.02.003) | CA dysregulation contributes to brain acidification in AD | High | | CAII/AD | [Curr Alzheimer Res 2019, Margheri et al.](https://doi.org/10.2174/1567205016666190516100512) | CA inhibition reduces Aβ-induced toxicity | High | | CA/PD | [Neurobiol Dis 2020, Gonzalez et al.](https://doi.org/10.1016/j.nbd.2020.104876) | CA modulation protects dopaminergic neurons | High | | CA/ALS | [Brain 2020, Priem et al.](https://doi.org/10.1093/brain/awaa123) | CA inhibition reduces excitotoxic damage | High | | CA/neuroinflame | [Neuropharmacology 2024, Cappetta et al.](https://doi.org/10.1016/j.neuropharm.2024.109780) | CA inhibition reduces neuroinflammation | High | | CA/BBB | [J Enzyme Inhib 2022, Supuran et al.](https://doi.org/10.1080/14756366.2022.2052856) | BBB penetration challenges for CA inhibitors | Medium |